NaDeNo Nanoscience AS
Nanotechnology for hard-to-deliver drugs
Nanotechnology for hard-to-deliver drugs
NaDeNo Nanoscience AS is a Norwegian startup with a focus on nanotechnology for hard-to-deliver drugs. Established in 2022, the company is a spin-off from SINTEF and is dedicated to developing a unique enabling nanotechnology platform for encapsulating highly hydrophobic small molecule drugs. With a goal to revolutionize drug delivery, NaDeNo presents a promising avenue for investment, offering innovative solutions to the challenges of delivering drugs that are traditionally hard to administer. As a venture capital firm considering potential investments, NaDeNo's pioneering technology and its potential impact on the pharmaceutical industry make it an intriguing prospect. With its location in Norway, known for its strong commitment to innovation and research, NaDeNo is well-positioned to leverage this conducive environment for technological advancements and attract investment opportunities.
There is no investment information
No recent news or press coverage available for NaDeNo Nanoscience AS.
We care about your data, and we'd love to use cookies make your experience better.
